GlassScriptPhysician profile
Marc Adelsheimer
NPI 1528066180
$677.20
in general payments reported to CMS, 2019-2025
12 companies · $33.38 in 2025
The $33.38 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $118 · 2021: $85.63 · 2022: $48.10 · 2023: $115 · 2024: $16.83 · 2025: $33.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $298.85 | 2019-2023 | Proclaim |
| Pfizer INC. | $71.06 | 2019-2021 | |
| Abbvie INC. | $66.77 | 2023-2025 | Botox |
| Mdd US Operations, LLC | $60.98 | 2019 | |
| Relievant Medsystems, INC. | $31.39 | 2023 | Intracept |
| Nevro Corp. | $29.67 | 2022 | |
| Allergan, INC. | $29.45 | 2020-2022 | |
| Bioventus LLC | $21.57 | 2023 | Stimrouter Implantable Kit |
| Electronic Waveform Lab, INC. | $20.87 | 2023 | |
| Si-Bone, INC. | $17.60 | 2020 | |
| Horizon Therapeutics Plc | $17.46 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Adelsheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.